Korean J Intern Med.
2019 Nov;34(6):1188-1196. 10.3904/kjim.2019.071.
Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
- Affiliations
-
- 1Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea.
- 2Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea. leptin72@gmail.com
- KMID: 2463475
- DOI: http://doi.org/10.3904/kjim.2019.071
Abstract
- The incidence of colorectal cancer (CRC) has increased. CRC is the third most common cancer and the fourth most common cause of cancer-related deaths in Korea. Palliative chemotherapy can be used to shrink tumors and ease symptoms caused by the cancer when cure is not possible. It is important to identify chemotherapeutic agents that can be used to effectively treat metastatic CRC (mCRC) and thus improve the survival and quality of life of patients with mCRC. This review aimed to evaluate the recent developments in palliative chemotherapy for mCRC and the biological or targeted agents used based on genetic alterations.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Chemotherapy for Patients with Colorectal Cancer - When and How?
- Recent advances in systemic chemotherapy for metastatic colorectal cancer
- Palliative Resection for Incurable Colorectal Cancer
- Usefulness of Carcinoembryonic Antigen for Monitoring Tumor Progression during Palliative Chemotherapy in Metastatic Colorectal Cancer
- Impact of Hyperglycemia on Survival and Infection-Related Adverse Events in Patients with Metastatic Colorectal Cancer Who Were Receiving Palliative Chemotherapy
